15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering Sarepta Therapeutics Inc, 7 rate it Buy or better, 3 sit at Hold, and 3 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $5.00 to $50.00 (about 10.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $25.75 sits 17% above the current $22.00. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 5 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.17 next quarter toward $2.57 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Moderate Buy
Strong Buy00%
Buy754%
Hold323%
Sell323%
Strong Sell00%
Based on 13 analysts giving stock ratings to Sarepta Therapeutics Inc.
As of Sep, 6 of 12 firms rate SRPT a Buy (3 Hold, 3 Sell), the standing distribution of every covering firm's most recent active call.
SRPT EPS & revenue forecast
EPS · NEXT QUARTER
$0.17
Range $-1.07 – $1.08 · 10 analysts · -105% YoY
Next period, 10 analysts expect Sarepta Therapeutics Inc to earn $0.17 a share (range $-1.07 – $1.08), versus $-3.58 a year earlier. Full-year consensus is $4.44, growing to $2.57 the year after.
REVENUE · NEXT QUARTER
$351.8M
Range $327.1M – $391.5M · 10 analysts · -21% YoY
Revenue is expected to reach $351.8M (range $327.1M – $391.5M), -20.6% year-over-year. Full-year consensus is $1.8B, rising to $1.4B next year.
Top analysts covering Sarepta Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SRPT.
#1
Anupam Rama
JP Morgan · Rank #75
Hold
$19.00-13.7% to target
Overall win rate
51%
+ Follow
#2
Debjit Chattopadhyay
Guggenheim · Rank #113
Buy
$19.00-13.7% to target
Overall win rate
44%
+ Follow
#3
Kristen Kluska
Cantor Fitzgerald · Rank #169
Hold
$21.00-4.6% to target
Overall win rate
38%
+ Follow
#4
Mitchell Kapoor
HC Wainwright & Co. · Rank #193
Sell
$5.00-77.3% to target
Overall win rate
34%
+ Follow
#5
Yigal Nochomovitz
Citigroup · Rank #245
Sell
$13.00-40.9% to target
Overall win rate
41%
+ Follow
SRPT stock forecast FAQ
What is SRPT's average 12-month price target?+
The 12 analysts with a live target average $25.75 for Sarepta Therapeutics Inc over the next 12 months, ranging from a $50.00 high to a $5.00 low.
Is SRPT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 13 analyst ratings, 7 are Buy or Strong Buy, 3 are Hold, and 3 are Sell or Strong Sell.
What are the highest and lowest price targets for SRPT?+
The Street-high target is $50.00 (BMO Capital), and the Street-low is $5.00 (HC Wainwright & Co.). The average of all 12 active targets is $25.75.
How many Wall Street analysts cover SRPT?+
13 analysts have an active rating on Sarepta Therapeutics Inc, and 12 firms carry a live 12-month price target.
Who is the most accurate analyst covering SRPT?+
Among analysts who currently cover SRPT, Anupam Rama of JP Morgan has the strongest overall Quantellect track record (Rank #75). Their current call is Hold with a $19.00 target.
What is Sarepta Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $0.17 per share (range $-1.07 – $1.08) across 10 analysts. Full-year EPS is projected at $4.44, rising to $2.57 the following year.
How much revenue is Sarepta Therapeutics Inc expected to report next quarter?+
Consensus revenue is $351.8M (range $327.1M – $391.5M). Full-year revenue is projected at $1.8B, growing to $1.4B next year.
Have analysts been upgrading or downgrading SRPT lately?+
As of Sep, 6 of 12 firms rate SRPT a Buy (3 Hold, 3 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SRPT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
